Hudson Valley Investment Advisors Inc. ADV Has $277,000 Holdings in Bristol Myers Squibb Company $BMY

Hudson Valley Investment Advisors Inc. ADV cut its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 41.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,989 shares of the biopharmaceutical company’s stock after selling 4,220 shares during the quarter. Hudson Valley Investment Advisors Inc. ADV’s holdings in Bristol Myers Squibb were worth $277,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. Franklin Street Advisors Inc. NC grew its holdings in Bristol Myers Squibb by 32.9% in the second quarter. Franklin Street Advisors Inc. NC now owns 472,621 shares of the biopharmaceutical company’s stock worth $21,878,000 after purchasing an additional 117,028 shares during the period. Ascent Group LLC grew its holdings in Bristol Myers Squibb by 0.6% in the second quarter. Ascent Group LLC now owns 53,506 shares of the biopharmaceutical company’s stock worth $2,477,000 after purchasing an additional 316 shares during the period. New Century Financial Group LLC acquired a new stake in Bristol Myers Squibb in the second quarter worth $1,161,000. DHJJ Financial Advisors Ltd. grew its holdings in Bristol Myers Squibb by 51.9% in the second quarter. DHJJ Financial Advisors Ltd. now owns 781 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 267 shares during the period. Finally, Abundance Wealth Counselors grew its holdings in Bristol Myers Squibb by 3.9% in the second quarter. Abundance Wealth Counselors now owns 36,399 shares of the biopharmaceutical company’s stock worth $1,691,000 after purchasing an additional 1,360 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on BMY shares. Daiwa America cut shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 5th. Dbs Bank upgraded shares of Bristol Myers Squibb to a “moderate buy” rating in a report on Thursday. Weiss Ratings reiterated a “hold (c)” rating on shares of Bristol Myers Squibb in a report on Saturday, September 27th. Wall Street Zen cut shares of Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Friday, June 6th. Finally, Daiwa Capital Markets cut shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price objective for the company. in a report on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, sixteen have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of “Hold” and an average price target of $56.38.

Bristol Myers Squibb Stock Down 0.7%

Bristol Myers Squibb stock opened at $45.39 on Friday. Bristol Myers Squibb Company has a fifty-two week low of $42.96 and a fifty-two week high of $63.33. The stock has a market cap of $92.38 billion, a PE ratio of 18.30, a price-to-earnings-growth ratio of 2.34 and a beta of 0.33. The firm’s 50-day simple moving average is $46.36 and its 200 day simple moving average is $48.65. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The business had revenue of $12.27 billion for the quarter, compared to analysts’ expectations of $11.32 billion. During the same period in the previous year, the company earned $2.07 earnings per share. The firm’s revenue for the quarter was up .6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Research analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd will be given a $0.62 dividend. The ex-dividend date of this dividend is Friday, October 3rd. This represents a $2.48 annualized dividend and a yield of 5.5%. Bristol Myers Squibb’s payout ratio is currently 100.00%.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the sale, the executive vice president owned 167,379 shares of the company’s stock, valued at approximately $7,922,048.07. The trade was a 25.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.09% of the company’s stock.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.